{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:11:43Z","timestamp":1789150303070,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":614,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1038\/mt.2014.218","type":"journal-article","created":{"date-parts":[[2014,11,10]],"date-time":"2014-11-10T12:15:58Z","timestamp":1415621758000},"page":"321-329","source":"Crossref","is-referenced-by-count":19,"title":["Case\u2013Control Estimation of the Impact of Oncolytic Adenovirus on the Survival of Patients With Refractory Solid Tumors"],"prefix":"10.1016","volume":"23","author":[{"given":"Anna","family":"Kanerva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anniina","family":"Koski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilkka","family":"Liikanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Oksanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Joensuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juni","family":"Palmgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akseli","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2014.218_bib1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3109\/02841860903071369","article-title":"Oncolytic adenovirus treatment of a patient with refractory neuroblastoma","volume":"49","author":"Pesonen","year":"2010","journal-title":"Acta Oncol"},{"key":"10.1038\/mt.2014.218_bib2","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/gt.2010.17","article-title":"Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5\/3-Cox2L-D24 in patients with metastatic and refractory solid tumors","volume":"17","author":"Pesonen","year":"2010","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2014.218_bib3","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1158\/0008-5472.CAN-09-3567","article-title":"Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients","volume":"70","author":"Cerullo","year":"2010","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2014.218_bib4","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1158\/1078-0432.CCR-09-3167","article-title":"Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors","volume":"16","author":"Nokisalmi","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2014.218_bib5","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Koski","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2014.218_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1021\/mp1002174","article-title":"Safety of glucocorticoids in cancer patients treated with oncolytic adenoviruses","volume":"8","author":"Rajecki","year":"2011","journal-title":"Mol Pharm"},{"key":"10.1038\/mt.2014.218_bib7","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/mt.2011.113","article-title":"Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus","volume":"19","author":"Cerullo","year":"2011","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2014.218_bib8","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1002\/ijc.26216","article-title":"Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors","volume":"130","author":"Pesonen","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1038\/mt.2014.218_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/mt.2011.230","article-title":"Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer","volume":"20","author":"Koski","year":"2012","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2014.218_bib10","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1158\/0008-5472.CAN-11-3001","article-title":"Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients","volume":"72","author":"Pesonen","year":"2012","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2014.218_bib11","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/mt.2012.115","article-title":"Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer","volume":"20","author":"Hemminki","year":"2012","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2014.218_bib12","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-12-2546","article-title":"Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus","volume":"19","author":"Kanerva","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2014.218_bib13","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/mt.2013.51","article-title":"Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients","volume":"21","author":"Liikanen","year":"2013","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2014.218_bib14","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ijc.28696","article-title":"Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans","volume":"135","author":"Bramante","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1038\/mt.2014.218_bib15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2014.218_bib16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2014.218_bib17","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.ygyno.2004.03.023","article-title":"Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials","volume":"93","author":"Markman","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1038\/mt.2014.218_bib18","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/COC.0b013e3182549399","article-title":"The use of Fluorouracil (5-FU) and leucovorin in women with heavily pretreated advanced ovarian carcinoma","volume":"36","author":"Peled","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"10.1038\/mt.2014.218_bib19","doi-asserted-by":"crossref","first-page":"9008a","DOI":"10.1200\/jco.2014.32.18_suppl.lba9008","volume":"32","author":"Kaufman","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1038\/mt.2014.218_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1054\/bjoc.1999.0866","article-title":"Position paper by the UKCCCR elderly cancer patients in clinical trials working group","volume":"82","author":"UKCCCR Elderly Cancer Patients in Clinical Trials Working Group","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1038\/mt.2014.218_bib21","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1200\/JCO.1994.12.5.888","article-title":"Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer","volume":"12","author":"Nixon","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1038\/mt.2014.218_bib22","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1002\/1097-0142(20011115)92:10<2523::AID-CNCR1603>3.0.CO;2-6","article-title":"Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience","volume":"92","author":"Xiong","year":"2001","journal-title":"Cancer"},{"key":"10.1038\/mt.2014.218_bib23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1034\/j.1600-065X.2002.18813.x","article-title":"GM-CSF-based cancer vaccines","volume":"188","author":"Dranoff","year":"2002","journal-title":"Immunol Rev"},{"key":"10.1038\/mt.2014.218_bib24","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1089\/hum.2013.123","article-title":"[(18)F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer","volume":"24","author":"Koski","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2014.218_bib25","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1158\/0008-5472.CAN-12-4124","article-title":"GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-a","volume":"73","author":"Kohanbash","year":"2013","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2014.218_bib26","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ccr.2012.04.025","article-title":"Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and t cell immunity in pancreatic cancer","volume":"21","author":"Bayne","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1038\/mt.2014.218_bib27","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","article-title":"Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia","volume":"21","author":"Pylayeva-Gupta","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1038\/mt.2014.218_bib28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12307-012-0126-7","article-title":"Tumor microenvironment and myeloid-derived suppressor cells","volume":"6","author":"Umansky","year":"2013","journal-title":"Cancer Microenviron"},{"key":"10.1038\/mt.2014.218_bib29","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"10.1038\/mt.2014.218_bib30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1042\/BST20120265","article-title":"Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes)","volume":"41","author":"Whiteside","year":"2013","journal-title":"Biochem Soc Trans"},{"key":"10.1038\/mt.2014.218_bib31","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2014.218_bib32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1158\/2326-6066.CIR-13-0062-T","article-title":"CD4+ T effectors specific for the tumor antigen NY-ESO-1 are highly enriched at ovarian cancer sites and coexist with, but are distinct from, tumor-associated Treg","volume":"1","author":"Ayyoub","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1038\/mt.2014.218_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1525-1438.2002.01093.x","article-title":"Immunology of the peritoneal cavity: relevance for host-tumor relation","volume":"12","author":"Melichar","year":"2002","journal-title":"Int J Gynecol Cancer"},{"key":"10.1038\/mt.2014.218_bib34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/08830185.2011.569902","article-title":"Peritoneal immune system in patients with advance epithelial ovarian cancer","volume":"30","author":"Wertel","year":"2011","journal-title":"Int Rev Immunol"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616300429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616300429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T05:40:51Z","timestamp":1566020451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616300429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S1525001616300429"],"URL":"https:\/\/doi.org\/10.1038\/mt.2014.218","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}